$4.40
Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Lifecore Biomedical to Participate at CPHI Global Conference
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity
Overview
52-week range
$3.63
$8.98
14% of range
Avg surprise (last 2)
-45.1%
Avg reaction (last 1)
-3.9%
0% positive
Latest IV / EM
204%
EM ±31.8% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.19 | — | — | — | — | financials |
| Wed May 6, 2026 | Mar/2026 | $-0.43 | $-0.24 | -79.2% | — | -3.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.29 | — | — | — | — | financials |
| Thu Aug 7, 2025 | May/2025 | $-0.10 | $-0.09 | -11.1% | — | — | earnings |
| Sun May 25, 2025 | May 2025 | $-0.06 | — | — | — | — | financials |
| Sun Feb 23, 2025 | Feb 2025 | $-0.42 | — | — | — | — | financials |
| Sun Nov 24, 2024 | Nov 2024 | $-0.25 | — | — | — | — | financials |
| Sun Aug 25, 2024 | Aug 2024 | $-0.53 | — | — | — | — | financials |
| Sun Feb 25, 2024 | Feb 2024 | $0.42 | — | — | — | — | financials |
| Sun Nov 26, 2023 | Nov 2023 | $0.39 | — | — | — | — | financials |
| Sun Aug 27, 2023 | Aug 2023 | $-0.35 | — | — | — | — | financials |
| Sun Feb 26, 2023 | Feb 2023 | $-1.20 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34M | $23M | — | $31M | $36M | $35M | $33M | $25M |
| Cost of revenue | $22M | $19M | — | $23M | $22M | $25M | $21M | $19M |
| Gross profit | $12M | $4M | — | $8M | $14M | $10M | $11M | $5M |
| Operating income | $3M | $-5M | — | $-3M | $5M | $-9M | $-2M | $-12M |
| Net income | $-6M | $-15M | — | $-10M | $-1M | $-15M | $-7M | $-16M |
| EPS (diluted) | $-0.19 | $-0.43 | — | $-0.29 | $-0.06 | $-0.42 | $-0.25 | $-0.53 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17M | $21M | $17M | $19M | — | $5M | $9M | $6M |
| Inventory | $25M | $28M | $29M | $34M | — | $35M | $39M | $42M |
| Total current assets | $84M | $78M | $82M | $84M | — | $84M | $82M | $74M |
| Total assets | $230M | $225M | $232M | $235M | — | $238M | $255M | $247M |
| Long-term debt | $155M | $149M | $142M | $136M | — | $125M | $111M | $106M |
| Total liabilities | $213M | $205M | $198M | $198M | — | $190M | $196M | $207M |
| Total equity | $-34M | $-28M | $-14M | $-11M | $1M | $2M | $15M | $-4M |